Clinical trials
Phase 2 Study clinical trials
Below are recruiting phase 2 study clinical trials, each written for real people, not researchers. We’re tracking 1,327 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07704580RecruitingPhase 1/Phase 2
Sarilumab for active rheumatoid arthritis
This trial tests sarilumab, an injected antibody that blocks a key protein involved in inflammation, for people with moderate-to-severe rheumatoid arthritis (RA) who haven't had success with standard treatments. The goal is to see if adding sarilumab can help control joint pain and swelling.
Centennial, ColoradoAges 18 years+ - NCT07704177RecruitingPhase 2
A study of trastuzumab rezetecan plus two other drugs for advanced bile duct cancer
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has HER2 protein on its cells. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–80 - NCT05312801RecruitingPhase 1
Testing BAFF CAR-T for relapsed or resistant non-Hodgkin lymphoma
This Phase 1 study tests a new immune cell treatment (BAFF CAR-T) for people with non-Hodgkin lymphoma that has come back or did not respond well to treatment. It aims to see how safe it is and whether it can help control the lymphoma.
Cleveland, OhioAges 18 years+ - NCT07692165RecruitingPhase 1/Phase 2
Testing INT-210 capsules for active ulcerative colitis
This trial tests an experimental capsule called INT-210 for people with active ulcerative colitis (UC) who haven't improved enough with standard treatments. It aims to see if the drug can help control symptoms and improve the condition.
Guangzhou, GuangdongAges 18–75 - NCT07694557RecruitingPhase 1
Safety and immune response study of YKYY025 RSV vaccine
This study tests a new RSV vaccine called YKYY025 in healthy adults. The main goal is to see if it is safe and to measure how the immune system responds.
Anning, YunnanAges 18 years+ - NCT07691125RecruitingPhase 4
Growth hormone for adults with short bowel syndrome
This trial tests whether a growth hormone injection (Saizeng®) can help adults with short bowel syndrome. The goal is to see if it improves how your body absorbs nutrients and fluids.
Xiamen, FujianAges 18 years+ - NCT07693426RecruitingPhase 1
Study of efsubaglutide alfa for obese teenagers
This trial tests an injection called efsubaglutide alfa to help obese teenagers lose weight. It requires following diet and exercise advice for at least 3 months before starting.
Beijing, Beijing MunicipalityAges 12–17 - NCT07684157RecruitingPhase 2
Testing a new drug for active rheumatoid arthritis
This trial tests an investigational drug called JAB-8263 for people with active rheumatoid arthritis. It aims to see if the drug can help reduce inflammation and improve symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT07672561RecruitingPhase 3
Testing a new pill for moderate to severe plaque psoriasis
This study tests an experimental pill called WD-890 to see if it can help people with moderate to severe plaque psoriasis. The pill is compared to a placebo (a pill with no medicine) to check if it is safe and works well.
Nanjing, JiangsuAges 18–75 - NCT07679113RecruitingPhase 1
IPG1094 drug safety test in healthy Chinese adults
This trial tests a new drug called IPG1094 in healthy people to see if it's safe and how the body handles it. Healthy volunteers may join to help find the right dose for future studies.
Shanghai, XuhuiAges 18–50 - NCT07679399RecruitingPhase 2
New combo therapy vs capecitabine for biliary tract cancer after surgery
This trial tests if a combination of immunotherapy (durvalumab), chemotherapy (GEMOX or GC), and a targeted therapy (lenvatinib) works better than standard capecitabine chemotherapy to prevent cancer from coming back after surgery for bile duct or gallbladder cancer.
BeijingAges 18–75 - NCT05435248RecruitingPhase 1/Phase 2
Study drug for advanced lung cancer with a specific EGFR change
This Phase 1/2 trial tests HS-10375, a study drug, in people with advanced or metastatic non-small-cell lung cancer (NSCLC) whose cancer has a specific EGFR mutation (C797S). It may help by targeting that mutation when standard treatments are not an option.
Guangzhou, GuangdongAges 18 years+ - NCT07668999RecruitingPhase 1
Study of ZYG24004 for athlete's foot caused by fungus
This trial tests a new medication called ZYG24004 for athlete's foot (tinea pedis) caused by specific fungi. It may be a treatment option for people who have not had success with other antifungal treatments.
Beijing, Beijing MunicipalityAges 18–65 - NCT07669571RecruitingPhase 1
Testing NS-079 in healthy volunteers
This study tests an experimental drug called NS-079 in healthy people to see how safe it is and how the body processes it. It may help researchers learn if the drug could be used for future treatments.
Adelaide, South AustraliaAges 18–55 - NCT07668154RecruitingPhase 2
Testing SKB571 for advanced head and neck cancer
This study tests a new drug called SKB571 for people whose head and neck cancer (a type called squamous cell carcinoma) has come back or spread and cannot be surgically removed. The goal is to see if the drug is safe and effective.
ChengduAges 18–75 - NCT07669779RecruitingPhase 2
Study of AK146D1 and AK112 for advanced lung cancer
This trial tests a combination of two experimental drugs, AK146D1 and AK112, for people with advanced non-small cell lung cancer that cannot be removed by surgery or treated with standard chemo-radiation. It aims to find out if this combination can shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75 - NCT07669454RecruitingPhase 3
Nuvastatic® for metastatic colorectal cancer
This trial tests a new capsule (Nuvastatic®) added to standard chemotherapy for people with metastatic colorectal cancer. The goal is to see if it helps shrink tumors and improve well-being.
Visakhapatnam, Andhra PradeshAges 18–65 - NCT07669220RecruitingPhase 2
Short radiation, immunotherapy, and chemo for advanced rectal cancer
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
GuangzhouAges 18–75 - NCT07670273RecruitingPhase 2
Drug combo for advanced HER2 bile duct cancer
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) as a first treatment for people with advanced HER2-positive or HER2-low bile duct or gallbladder cancer. The goal is to see if this combination helps shrink or control the cancer.
BeijingAges 18–75 - NCT07670013RecruitingPhase 2
SKB264 and glecirasib for advanced KRAS G12C lung cancer
This trial tests a new combination of two drugs (SKB264 and glecirasib) for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It aims to see if this combination can shrink tumors or slow their growth.
Hangzhou, ZhejiangAges 18–75 - NCT06190886RecruitingPhase 1
First-in-human study of PTX-912 for advanced solid tumors
This trial tests a new drug called PTX-912 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It is a first-in-human study, meaning this is the first time PTX-912 is being given to people, to see how safe it is and how well it works.
Duarte, CaliforniaAges 18 years+ - NCT07662759RecruitingPhase 3
Study of TFC-003 for open-angle glaucoma or high eye pressure
This trial tests a new eye drop combination (TFC-003) to lower eye pressure in people with primary open-angle glaucoma or ocular hypertension. It compares the new drug to existing treatments to see if it works better or is safer.
SeongnamAges 19 years+ - NCT07647510RecruitingPhase 3
Testing Claseprubart for Generalized Myasthenia Gravis
This study tests whether a new drug called claseprubart can help adults with generalized myasthenia gravis (a condition where muscles get weak and tired easily). The drug works by targeting part of the immune system that damages muscles.
Pasadena, CaliforniaAges 18–80 - NCT07647328RecruitingPhase 3
Camizestrant and ribociclib for advanced hormone-receptor-positive breast cancer
This trial tests a combination of two drugs (camizestrant and ribociclib) for advanced breast cancer that is hormone-receptor-positive and HER2-negative. The study aims to see if this combination helps patients whose cancer cannot be surgically removed or treated with radiation alone.
Duarte, CaliforniaAges 18–130
Hear when a new Phase 2 Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for phase 2 study?
- Yes. Clin2 currently lists 1,327 recruiting phase 2 study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a phase 2 study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a phase 2 study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.